CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

When, where, and how to target vascular inflammation in the post-CANTOS era? Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT Informed Shared Decisions for Patients with Aortic Stenosis 2020 AHA/ACC Key Data Elements and Definitions for Coronary Revascularization A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Coronary Revascularization) The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008